ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 18.3 | 12.0 | 11.3 |
| Other income | 0.1 | 0.3 | 0.2 |
| Total income | 18.5 | 12.3 | 11.5 |
| Profit before exceptional items & tax | 2.0 | 1.9 | 1.2 |
| Exceptional items | 0.0 | 0.0 | 0.3 |
| Profit before tax | 2.0 | 1.9 | 1.6 |
| Net profit | 1.5 | 1.4 | 1.2 |
| Operating margin | 10.8% | 15.4% | 13.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +25.00% |
|---|---|
| Net profit, quarter on quarter | +7.10% |
| Revenue, year on year | +61.90% |
BSE results filing, BSE: 540204. Figures extracted from the filing.
Eiko Lifesciences Ltd: key numbers
- Share price
- ₹48.39
- Market cap
- ₹66.40 Cr
- Revenue (annual)
- ₹52.57 Cr
- Net profit (annual)
- ₹4.50 Cr
- P/E (TTM)
- 12.8×Sector 35.5×
- Promoter holding
- 39.96%+0.05% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Eiko Lifesciences Ltd
All →Eiko Lifesciences Merger & Restructuring
Eiko Lifesciences' wholly owned subsidiary Eiko Scientific Solutions LLP will form a 50:50 joint venture, Oval Eiko Resources, with Oval Projects Engineering. The JV targets compressed bio gas production and distribution.
Eiko Lifesciences Q2 FY27 Results: Net Profit ₹1.6 Cr, Up 23.1% YoY
Eiko Lifesciences Ltd reported revenue from operations of ₹17.7 Cr (+51.3% YoY) and net profit of ₹1.6 Cr (+23.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1.6 Cr · +23.1% YoY
Eiko Lifesciences Board Meeting Date
Eiko Lifesciences has scheduled a board meeting for November 5, 2026, to approve unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The trading window stays closed until 48 hours after the results.
Eiko Lifesciences Convertible Warrants
Eiko Lifesciences allotted 1,50,000 equity shares upon conversion of warrants, receiving a balance payment of Rs. 0.62 Crore from promoter Lenus Finvest Private Limited.
- Value
- ₹0.62 Cr
- From
- Lenus Finvest Private Limited
Eiko Lifesciences Other Announcement
The company submitted the Regulation 74(5) compliance certificate from its Registrar and Share Transfer Agent for the quarter ended September 30, 2026.
Eiko Lifesciences Annual General Meeting
Eiko LifeSciences held its 49th Annual General Meeting on September 22, 2026. The meeting transacted business, including adoption of financial statements and appointment of directors.